《新股消息》中证监已接收蚂蚁集团申请境外上市审批材料
据中国证监会官网消息,蚂蚁集团申请境外首次公开发行股份,包括普通股、优先股等各类股票及股票的派生形式,证监会已接收审批材料。
据市场消息指,蚂蚁集团在两地上市计划中的估值目标为2,250亿美元,公司在香港和上海IPO中的筹资目标为300亿美元。 蚂蚁集团据悉将计划在数周内提交香港和上海的IPO申请,料最早於10月份在两地上市。
早前浙江监管局官网亦公示了蚂蚁科技集团股份有限公司辅导备案文件。
文件显示,蚂蚁集团正在接受辅导机构中金公司、中信建投的科创板上市辅导。
备案文件还披露了蚂蚁集团持股5%以上的股东,分别为杭州君瀚股权投资合夥企业、杭州君澳股权投资合夥企业和杭州阿里巴巴网路科技有限公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.